References
1. Yung M, James A, Merkus P, et al. International Otology Outcome Group and the International Consensus on the Categorization of Tympanomastoid Surgery. J Int Adv Otol 2018;14 (2):216-26 doi: 10.5152/iao.2018.5553[published Online First: Epub Date]|.
2. Kurien G, Greeff K, Gomaa N, Ho A. Mastoidectomy and mastoid obliteration with autologous bone graft: a quality of life study. J Otolaryngol Head Neck Surg 2013;42 :49 doi: 10.1186/1916-0216-42-49[published Online First: Epub Date]|.
3. Yung M, Bennett A. Use of mastoid obliteration techniques in cholesteatoma. Curr Opin Otolaryngol Head Neck Surg 2013;21 (5):455-60 doi: 10.1097/MOO.0b013e3283646521[published Online First: Epub Date]|.
4. Trinidade A, Skingsley A, Yung MW. Pediatric cholesteatoma surgery using a single-staged canal wall down approach: results of a 5-year longitudinal study. Otol Neurotol 2015;36 (1):82-5 doi: 10.1097/MAO.0000000000000598[published Online First: Epub Date]|.
5. Valimaki VV, Aro HT. Molecular basis for action of bioactive glasses as bone graft substitute. Scand J Surg 2006;95 (2):95-102 doi: 10.1177/145749690609500204[published Online First: Epub Date]|.
6. Drago L, De Vecchi E, Bortolin M, Toscano M, Mattina R, Romano CL. Antimicrobial activity and resistance selection of different bioglass S53P4 formulations against multidrug resistant strains. Future Microbiol 2015;10 (8):1293-9 doi: 10.2217/FMB.15.57[published Online First: Epub Date]|.
7. Lepparanta O, Vaahtio M, Peltola T, et al. Antibacterial effect of bioactive glasses on clinically important anaerobic bacteria in vitro. J Mater Sci Mater Med 2008;19 (2):547-51 doi: 10.1007/s10856-007-3018-5[published Online First: Epub Date]|.
8. Munukka E, Lepparanta O, Korkeamaki M, et al. Bactericidal effects of bioactive glasses on clinically important aerobic bacteria. J Mater Sci Mater Med 2008;19 (1):27-32 doi: 10.1007/s10856-007-3143-1[published Online First: Epub Date]|.
9. Bernardeschi D, Nguyen Y, Russo FY, Mosnier I, Ferrary E, Sterkers O. Cutaneous and Labyrinthine Tolerance of Bioactive Glass S53P4 in Mastoid and Epitympanic Obliteration Surgery: Prospective Clinical Study. Biomed Res Int 2015;2015 :242319 doi: 10.1155/2015/242319[published Online First: Epub Date]|.
10. Bernardeschi D, Pyatigorskaya N, Russo FY, et al. Anatomical, functional and quality-of-life results for mastoid and epitympanic obliteration with bioactive glass s53p4: a prospective clinical study. Clin Otolaryngol 2017;42 (2):387-96 doi: 10.1111/coa.12748[published Online First: Epub Date]|.
11. Silvola JT. Mastoidectomy cavity obliteration with bioactive glass: a pilot study. Otolaryngol Head Neck Surg 2012;147 (1):119-26 doi: 10.1177/0194599812438168[published Online First: Epub Date]|.
12. Merchant SN, Wang P, Jang CH, et al. Efficacy of tympanomastoid surgery for control of infection in active chronic otitis media. Laryngoscope 1997;107 (7):872-7 doi: 10.1097/00005537-199707000-00007[published Online First: Epub Date]|.
13. Saleh HA, Mills RP. Classification and staging of cholesteatoma. Clin Otolaryngol Allied Sci 1999;24 (4):355-9 doi: 10.1046/j.1365-2273.1999.00272.x[published Online First: Epub Date]|.